EGFR and glioblastoma: In preclinical studies, treatment with HER1/EGFR-targeted agents such as monoclonal antibodies or small-molecule inhibitors, e.g. erlotinib (Tarceva; Genentech Inc.)were shown to exert promising antineoplastic activity in various in vitro and in vivo models in the setting of GBM [52, 54, 55].